Navigation Links
Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance
Date:12/10/2007

ALLEGAN, Mich., Dec. 10 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole delayed-release tablets. As the exclusive marketer and distributor of this product for the store brand over-the-counter (OTC) market in the United States, Perrigo expects to begin shipping its product during the first quarter of calendar year 2008, with full year annual sales to be in the range of $150 - $200 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "The approval from the FDA is the final regulatory step for this exclusive product launch, which we expect to be the largest product in Perrigo's 120 year history. While we are excited about the opportunity, we will obviously continue investing in research and development to add more new products to our product offering. The launch of Omeprazole is another example of Perrigo's dedication to make quality healthcare more affordable."

Based on pre-launch estimates, Perrigo's Omeprazole product is expected to contribute between $0.20 and $0.25 earnings per share in fiscal year 2008. As a result of the Omeprazole launch, full year earnings for fiscal year 2008 are expected to be in the range of $1.32 to $1.47 per share.

Prilosec OTC(R) is indicated for the treatment of frequent heartburn and had estimated current annual sales of approximately $750 million in all outlets.

Headquartered in Or Akiva, Israel, Dexcel Pharma Technologies, Ltd. is a privately-held, international specialty pharmaceutical company which focuses on the development, manufacture and marketing of innovative prescription, generic prescription, and OTC
'/>"/>

SOURCE The Perrigo Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... A newly launched ... ideas to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance ... two cash prizes of US$15,000 and a period of expert mentorship from a senior ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... The maximum ... of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On June ... the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... at the Swedish medical university Karolinska Institutet shows that ... LDL cholesterol and thereby cause an inflammation that leads ... cell receptors, the researchers have managed to inhibit the ... online in the distinguished periodical Journal of Experimental ...
... Concludes restatement of prior financial results , , ... call at 4:30 EDT today , , ... May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) (the "Company") today ... Company also announced today that it filed its Annual Report on Form 10-K for the ...
... The Netherlands , May 6, 2010 ... CRXL ; Swiss,Exchange: CRX) today announced the award from ... its paediatric vaccine Quinvaxem(R) to the developing,world. Paediatric vaccination ... Development Goals set by the United Nations, in,particular the ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Oncothyreon reports full year and fourth quarter 2009 financial results 2Oncothyreon reports full year and fourth quarter 2009 financial results 3Oncothyreon reports full year and fourth quarter 2009 financial results 4Oncothyreon reports full year and fourth quarter 2009 financial results 5Oncothyreon reports full year and fourth quarter 2009 financial results 6Oncothyreon reports full year and fourth quarter 2009 financial results 7Oncothyreon reports full year and fourth quarter 2009 financial results 8Oncothyreon reports full year and fourth quarter 2009 financial results 9Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 2Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 3Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 4
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards has received ... in the company,s portfolio from one of its module partners ... mainly take place during the third quarter 2015. The sensors ... . Jörgen Lantto, CEO of FPC, comments: ...   growing interest from smartphone OEMs in integrating touch fingerprint ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... Chip" developed at the University of Colorado at Boulder ... strains from patient samples within hours may help world ... last month on the new technology by the Centers ... CU-Boulder Flu Chip can determine the genetic make-up of ...
... old, in fact, which comes as a surprise to a ... the world's largest tropical region. , Using radiocarbon dating methods, ... up to half of all trees greater than 10 centimeters ... the trees, Trumbore said, are as much as 750 to ...
... (NCI) and the National Human Genome Research Institute ... Health (NIH), today launched a comprehensive effort to ... cancer through the application of genome analysis technologies, ... The Cancer Genome Atlas (TCGA), will begin with ...
Cached Biology News:New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 3New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 4Amazon trees much older than assumed, raising questions on global climate impact of region 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4
... White crystalline solid. PACKAGED UNDER ... Contaminants: DNases, proteases, RNases: none ... nm): ≤0.500; (100 mM, 1 cm, 280 ... Soluble in H 2 O. RTECS ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... productivity and allows you to achieve a higher ... beyond traditional paper-based weighing processes into a powerful ... Control of ... PR, SR, PG-S, PG, SG, AT, MT, UMT, ...
Biology Products: